Pulmatrix
Clinical-stage biopharmaceutical company developing inhaled therapies for serious lung diseases using its proprietary iSPERSE technology platform for optimized pulmonary drug delivery.
Website
https://www.pulmatrix.comLocation
Lexington, Massachusetts, USA
Founded
2003
Investors
1
Categories
biotech, respiratory, drug-delivery, pulmonary-diseases
Notes
Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies for serious lung diseases. The company's proprietary iSPERSE (inhaled Small Particles Easily Respirable and Emitted) technology enables optimized delivery of drugs directly to the lungs.
Pulmatrix focuses on developing treatments for pulmonary diseases including fungal infections, inflammatory conditions, and other respiratory disorders.
Team
- Robert Clarke, Ph.D. - Chief Executive Officer
- Ted Smith - Chief Financial Officer
Additional Research Findings
- Founded in 2003 in Lexington, Massachusetts
- Listed on NASDAQ (ticker: PULM)
- Portfolio company of Polaris Partners
- Proprietary iSPERSE drug delivery platform
- Lead program PUR1900 for pulmonary fungal infections
- Focus on inhaled therapies for lung diseases
- Platform enables efficient pulmonary drug delivery
- Targeting diseases with limited treatment options
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |